Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMT NASDAQ:AKCA NASDAQ:ARVN OTCMKTS:BLUSF NASDAQ:ESPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.80+3.6%$7.87$5.90▼$29.61$694.53M2.392.37 million shs5.05 million shsBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsESPREsperion Therapeutics$2.72+7.5%$2.42$0.69▼$3.94$510.11M0.968.60 million shs7.20 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas+3.59%+1.87%+26.61%+32.43%-62.50%BLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics+7.51%-12.82%-4.23%+140.71%+38.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$9.80+3.6%$7.87$5.90▼$29.61$694.53M2.392.37 million shs5.05 million shsBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsESPREsperion Therapeutics$2.72+7.5%$2.42$0.69▼$3.94$510.11M0.968.60 million shs7.20 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas+3.59%+1.87%+26.61%+32.43%-62.50%BLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics+7.51%-12.82%-4.23%+140.71%+38.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune Therapeutics 0.00N/AN/AN/AAKCAAkcea Therapeutics 0.00N/AN/AN/AARVNArvinas 2.48Hold$16.2966.22% UpsideBLUSFBELLUS Health 0.00N/AN/AN/AESPREsperion Therapeutics 2.50Moderate Buy$7.00157.35% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, BLUSF, ARVN, AKCA, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$16.009/27/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025ARVNArvinasBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$10.009/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.009/18/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $9.009/18/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $10.009/18/2025ARVNArvinasStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $14.009/17/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ARVNArvinas$263.40M2.73N/AN/A$8.17 per share1.20BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00ESPREsperion Therapeutics$332.31M1.65$0.03 per share105.30($1.97) per share-1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)BLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AESPREsperion Therapeutics-$51.74M-$0.49N/AN/A136.39-35.84%N/A-28.41%11/6/2025 (Estimated)Latest ESPR, BLUSF, ARVN, AKCA, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40AKCAAkcea TherapeuticsN/A12.1711.78ARVNArvinasN/A5.645.64BLUSFBELLUS HealthN/A13.8713.87ESPREsperion TherapeuticsN/A1.150.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%AKCAAkcea Therapeutics19.27%ARVNArvinas95.19%BLUSFBELLUS HealthN/AESPREsperion Therapeutics47.39%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%AKCAAkcea Therapeutics1.50%ARVNArvinas4.73%BLUSFBELLUS Health24.17%ESPREsperion Therapeutics1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableARVNArvinas42073.42 million69.95 millionOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableESPR, BLUSF, ARVN, AKCA, and AIMT HeadlinesRecent News About These CompaniesEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages5 hours ago | marketbeat.comWhy Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement NewsOctober 11 at 4:49 PM | uk.finance.yahoo.comEsperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price DropOctober 11 at 4:49 PM | finance.yahoo.comESPR Stock Drops 17% on Pricing of $75M Common Stock OfferingOctober 9, 2025 | zacks.comEsperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Down - Should You Sell?October 8, 2025 | marketbeat.comEsperion Announces Pricing of Public Offering of Common StockOctober 7, 2025 | globenewswire.comEsperion stock tumbles after announcing public offeringOctober 7, 2025 | investing.comEsperion Announces Proposed Public Offering of Common StockOctober 7, 2025 | globenewswire.comESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock UpOctober 6, 2025 | zacks.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Time to Buy?October 3, 2025 | marketbeat.comEsperion Shares Rally After Patent Litigation Settlement For Cholesterol DrugsOctober 3, 2025 | msn.comEsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid ...October 3, 2025 | finance.yahoo.comEsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040October 3, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Trading Up 8.9% - Still a Buy?October 1, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Raised to Buy at Wall Street ZenSeptember 26, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Trading Up 6.7% - What's Next?September 25, 2025 | marketbeat.comUMB Bank n.a. Takes $167,000 Position in Esperion Therapeutics, Inc. $ESPRSeptember 24, 2025 | marketbeat.comEsperion Therapeutics, Inc. $ESPR Shares Bought by Parallel Advisors LLCSeptember 24, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Still a Buy?September 20, 2025 | marketbeat.comEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at HC WainwrightSeptember 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, BLUSF, ARVN, AKCA, and AIMT Company DescriptionsAimmune Therapeutics NASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Akcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Arvinas NASDAQ:ARVN$9.80 +0.34 (+3.59%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$9.76 -0.04 (-0.41%) As of 09:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.BELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Esperion Therapeutics NASDAQ:ESPR$2.72 +0.19 (+7.51%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$2.67 -0.05 (-1.84%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
